IgG Cleavage Detection and Effector Function Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack robust assays for detecting IgG cleavage products in bodily fluids due to low concentrations and technical challenges in distinguishing them from intact immunoglobulin, and there is no therapeutic strategy to restore IgG functions compromised by protease-mediated cleavage.
Innovation Solution
Development of reagents and methods to detect IgG cleavage products, including antibodies specific for cleavage sites, and administration of peptides representing these sites to restore effector functions of IgG molecules degraded by proteases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for IgG cleavage products, then the assay complexity is reduced, but the detection precision is insufficient due to low concentrations and difficulty in distinguishing from intact immunoglobulin
Solution Approach 1:
The invention segments the detection process into multiple stages: first capturing intact IgG on solid phase, then selectively detecting cleaved fragments in the supernatant. This segmentation allows differentiation between intact and cleaved IgG, resolving the precision issue while maintaining manageable assay complexity through structured workflow division.
Solution Approach 2:
The invention extracts the cleaved IgG fragments from the complex mixture by capturing intact IgG on solid phase and analyzing the supernatant for fragments. This extraction approach isolates the target analyte from interfering substances, significantly improving detection precision without requiring overly complex analytical instrumentation.
2Reliability
If protease activity is allowed to proceed without intervention, then the natural disease process is reflected, but the IgG effector functions are compromised and lost
Solution Approach 1:
The invention applies preliminary anti-action by administering protease inhibitors or protective antibodies before complete cleavage occurs. This prevents the harmful proteolytic degradation while still allowing sufficient protease activity to maintain disease indicator reliability, thus protecting IgG effector functions from complete loss.
Solution Approach 2:
The invention converts the harmful proteolytic cleavage into a beneficial diagnostic opportunity by detecting cleaved fragments as disease biomarkers. The protease activity that would normally destroy IgG function is instead utilized to generate detectable markers of disease activity, while therapeutic interventions protect the effector functions.
3Quantity of substance
If no specific detection reagents are used, then the manufacturing cost is reduced, but the ability to detect low concentration cleavage products is insufficient
Solution Approach 1:
The invention employs universal detection reagents such as anti-IgG antibodies that can detect both intact and cleaved forms through different assay configurations. This multi-functionality approach achieves high detection sensitivity for low concentration fragments without requiring development of entirely new reagents, thus balancing sensitivity with manufacturing feasibility.
Solution Approach 2:
The invention uses excessive amounts of capture antibodies on solid phase to ensure complete capture of intact IgG, thereby enriching the supernatant for cleaved fragments. This partial/excessive action approach compensates for low fragment concentrations and achieves high detection sensitivity without requiring complex concentration or purification steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the detection of IgG cleavage as a biomarker for disease activity and restoration of IgG effector functions, enhancing diagnostic and therapeutic capabilities for diseases characterized by protease activity.
Implementation Method 1
Human proteases such as matrix metalloproteinases (MMPs) and neutrophil elastase cleave the IgGs heavy chain polypeptide at a residue unique to each protease
Implementation Method 2
a specific antibody was prepared for detection of human neutrophil elastase cleaved Fc domain
Data Source
AI summary
The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.